Skip to main content
spacbrain

Estrella Immunopharma

Closed (deSPAC)

Health Care · T-cell therapies for blood cancers and solid tumors

What it is
Estrella, a Delaware corporation, is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors
What it’s doing now
Merging with TradeUP Acquisition Corp. (UPTD) — closed (despac).
What you should know
Data is still being assembled for this company — what is shown below is everything we have verified so far.

The business, per its filings

SEC primary

Estrella, a Delaware corporation, is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella’s mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Source: S-4/A, accession 0001213900-23-055627

What the company says about itself

Web research — not audited
What our web check found

[WEB-INTEL 2026-08-26] 5 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Aggregate gross proceeds to the Company from both transactions are expected to be approximately $8.0 million." [https://www.stocktitan.net/news/ESLA/estrella-immunopharma-inc-announces-8-0-million-registered-direct-m3ro8iwy038w.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The offering price per Common Unit is $1.58 (or $1.5799 for each Pre-Funded Unit...)" [https://www.stocktitan.net/news/ESLA/estrella-immunopharma-inc-announces-8-0-million-registered-direct-m3ro8iwy038w.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Each PIPE Common Warrant is exercisable for one (1) share of Common Stock at an exercise price of $1.39." [https://www.stocktitan.net/news/ESLA/estrella-immunopharma-inc-announces-8-0-million-registered-direct-m3ro8iwy038w.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction, valuing the post-combination combined entity at $325 million, was announced on October 3, 2022, and was closed on September 29, 2023." [https://www.rc.com/experience/represents-tradeup-acquisition-corp-in-complex-despac-transaction-with-estrella-biopharma-inc] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Deadline for Merger With Estrella Biopharma ・ from September 19, 2023 to October 19, 2023, $37,432.70 ・ on September 30, 2022." [https://firstwordpharma.com/story/5782114] [WEB-INTEL 2026-08-26] 6 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Aggregate gross proceeds to the Company from both transactions are expected to be approximately $8.0 million." [https://www.stocktitan.net/news/ESLA/estrella-immunopharma-inc-announces-8-0-million-registered-direct-m3ro8iwy038w.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The offering price per Common Unit is $1.58 (or $1.5799 for each Pre-Funded Unit...)" [https://www.stocktitan.net/news/ESLA/estrella-immunopharma-inc-announces-8-0-million-registered-direct-m3ro8iwy038w.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Each PIPE Common Warrant is exercisable for one (1) share of Common Stock at an exercise price of $1.39." [https://www.stocktitan.net/news/ESLA/estrella-immunopharma-inc-announces-8-0-million-registered-direct-m3ro8iwy038w.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "investment in public equity (“PIPE”) financing that is expected to result in approximately $3.35 million in gross proceeds." [https://www.estrellabio.com/news/estrella-immunopharma-announces-approximately-%243.35-million-private-placement-equity-financing] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Deadline for Merger With Estrella Biopharma ・ from September 19, 2023 to October 19, 2023" [https://firstwordpharma.com/story/5782114] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction, valuing the post-combination combined entity at $325 million" [https://www.rc.com/experience/represents-tradeup-acquisition-corp-in-complex-despac-transaction-with-estrella-biopharma-inc]

Source: company web presence · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

Estrella Immunopharma is merging with TradeUP Acquisition Corp. (UPTD) currently marked Closed (deSPAC).

Headline equity value—
PIPE≈ $3M · unsourced

Structure per SEC accession(s) 0001213900-25-050329. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Estrella Immunopharma going public?

Estrella Immunopharma has an approved merger with the SPAC TradeUP Acquisition Corp. (UPTD). Deal status: Closed (deSPAC).

Does Estrella Immunopharma have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals